Mechanistically, METTL16-mediated m6A modification reduces MXD4 mRNA stability, leading to decreased MXD4 protein levels, which indirectly activates the MYC–MAX complex and downstream target gene expression, thereby promoting AML cell proliferation and survival. Here, MXD4 is linked to acute myeloid leukemia.